InMed Pharmaceuticals
Logotype for InMed Pharmaceuticals Inc

InMed Pharmaceuticals (INM) investor relations material

InMed Pharmaceuticals has been delisted

InMed Pharmaceuticals Q1 2027 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for InMed Pharmaceuticals Inc
Q1 2027 earnings summary3 Nov, 2026

Executive summary

  • Q1 FY2027 net loss was $2.331M versus $1.727M a year earlier; cash and cash equivalents were $1.094M at September 30, 2026.

  • Operations are focused on pharmaceutical R&D after BayMedica Commercial wound down; significant resources are not currently planned for advancing drug candidates.

  • Proposed Mentari merger and ~US$490M in private-placement financing are central to the outlook; proposed CVRs could provide eligible shareholders with proceeds from future legacy-asset monetization, but none are assured.

Financial highlights

  • Continuing-operations net loss was $1.995M versus $1.830M; total net loss included a $336K discontinued-operations loss versus $103K income a year earlier.

  • Continuing-operations operating expenses were $2.009M, up 4% YoY; R&D expense fell 64% to $206K, while G&A rose 46% to $1.803M, primarily on merger costs.

  • Basic and diluted loss per share was $0.42 versus $0.44 YoY; continuing-operations loss per share was $0.36 versus $0.46.

  • Cash used in operating activities was $1.142M versus $1.931M a year earlier; quarter-end cash and cash equivalents were $1.094M versus $2.194M at June 30, 2026.

Outlook and guidance

  • Available cash was expected to fund planned operating and capital needs into mid-November, subject to spending and merger timing; additional capital is required to sustain operations.

  • Merger closing was expected in Q4 2026, subject to closing conditions and required approvals; Mentari financing is intended to support operations into 2029 and through Phase 2a readouts for two lead PACAP-targeted programs.

  • If the merger does not close, funding or strategic transactions may be pursued; capital may not be secured on acceptable terms or at all.

  • If the merger does not proceed and funding is obtained, R&D expense is expected to rise substantially; no material product-candidate revenue is expected for several years, if ever.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.
InMed Pharmaceuticals
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

InMed Pharmaceuticals Inc is a Canadian biotechnology company specializing in the research and development of rare cannabinoids. The company focuses on creating pharmaceutical and consumer health products derived from cannabinoid compounds using biosynthesis and chemical synthesis technologies. Its operations span proprietary drug development and manufacturing services. InMed Pharmaceuticals Inc is headquartered in Vancouver, Canada, and its shares are listed on the NASDAQ.